Sysmex (OTCMKTS:SSMXY) Shares Gap Up – Here’s What Happened

Sysmex Corporation ADR (OTCMKTS:SSMXY) shares gapped up before the market opened on Monday . The stock had previously closed at $9.15, but opened at $9.79. Sysmex shares last traded at $9.80, with a volume of 2,851 shares traded.

Analyst Ratings Changes

Separately, Zacks Research downgraded shares of Sysmex from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold”.

Sysmex Trading Up 5.0%

The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 2.46. The company has a market capitalization of $6.14 billion, a price-to-earnings ratio of 25.66 and a beta of 1.07. The business’s 50-day moving average price is $9.08 and its two-hundred day moving average price is $9.06.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The company had revenue of $877.92 million for the quarter, compared to analyst estimates of $862.45 million. Sysmex had a return on equity of 7.23% and a net margin of 7.13%.Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. Research analysts predict that Sysmex Corporation ADR will post 0.42 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.